Aptar Pharma is pleased to announce the co-organization and its diamond sponsorship of the third Respiratory Drug Delivery (RDD®) Asia scientific conference, which will take place at the Grand Hyatt Kochi hotel from November 14-16 in Kerala, India.
In addition to co-organizing the conference and exhibiting, Aptar Pharma will host an interactive workshop on Thursday, November 15 addressing the most recent FDA guidance on Combination Products, with a focus on respiratory and nasal drug products. The seminar, entitled “Decoding FDA’s Recent Combination Drug Product Guidance: Applications to DPIs, pMDIs, and Nasal Sprays,” will be presented by Badre Hammond, Associate Director, Market Development at Aptar Pharma. This workshop, which will be repeated three times during the day, will give insights into optimal approaches to help secure approval in this changing and challenging regulatory landscape. It will review various topics, including the definition of combination products, NDA/ANDA submissions, regulatory pathway review, Human Factor studies in the context of combination products, and clarify expectations on the sponsor, the device supplier and regulators.
Furthermore, Dr. Gerallt Williams, Director of Scientific Affairs at Aptar Pharma, will present a poster entitled “Interpretation Of Manual Actuation Profiles From Nasal Bi-dose Spray Devices”, which demonstrates their impact on analytical and regulatory requirements.
Building on the successes of previous RDD conferences in the U.S., Europe and Asia, RDD Asia 2018 is recognized as one of the premium international meetings in the area. More than 200 delegates from Asia and beyond are expected to attend.
To connect with Aptar Pharma at RDD Asia 2018 and meet their team of experts, register at:
Press release: Aptar Pharma organizer and Sponsor at Respiratory Drug Delivery Asia.